One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
A manufacturer document retrieved from a URL containing 2024-09 is actually revised July 2026. Its renal avoid-use restriction remains separate from newer hepatic dosing instructions.
What to reconcile: Read the document revision, not the URL folder date. Do not apply the hepatic dose reduction as a renal workaround.
Open this note and its source referencesRead the document revision, not the URL folder date. Do not apply the hepatic dose reduction as a renal workaround.
The usual regimen is 200 mg twice daily. A lower severe-hepatic dose does not create a severe-renal regimen.
Review hemorrhage, QT/electrolytes, diarrhea, infection and interactions. Strong CYP3A4 inhibitors or inducers are contraindicated. No dialysis replacement dose is inferred.
| Printed eGFR (mL/min) | Source-specific instruction |
|---|---|
| <30 | Avoid use |
| 30-89 | Exposure similar to >=90 in the selected renal PK study; this is not an all-patient dosing authorization |
VONJO - renal restriction
| Printed eGFR (mL/min) | Source-specific instruction |
|---|---|
| <30 | Avoid use |
| 30-89 | Exposure similar to >=90 in the selected renal PK study; this is not an all-patient dosing authorization |
The usual regimen is 200 mg twice daily. A lower severe-hepatic dose does not create a severe-renal regimen.
Review hemorrhage, QT/electrolytes, diarrhea, infection and interactions. Strong CYP3A4 inhibitors or inducers are contraindicated. No dialysis replacement dose is inferred.
RDM64-official-pacritinib-vonjo-bb997138e1-C1 · Source locator: Sections 1, 2.1-2.2, 4, 8.7 and 12.3; PDF renal PK page inspected.
The usual regimen is 200 mg twice daily. A lower severe-hepatic dose does not create a severe-renal regimen.
Review hemorrhage, QT/electrolytes, diarrhea, infection and interactions. Strong CYP3A4 inhibitors or inducers are contraindicated. No dialysis replacement dose is inferred.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=pacritinib-vonjo&s1=RDM64-official-pacritinib-vonjo-bb997138e1&h1=3e63ba3e34e2c90a151b32395116683273a06491eff52ed5ab7d773dcd7e9197